Rising Measles And Chickenpox Cases Drive Growth In The Market: A Key Factor Shaping the Future of the Proquad Market in 2025

What industry-specific factors are fueling the growth of the proquad market?
The rising incidence of measles and chickenpox is expected to propel the growth of the Proquad market going forward. Measles is a highly contagious viral infection characterized by fever, cough, and a red rash, preventable through vaccination, while chickenpox is a contagious disease caused by the Varicella-zoster virus, marked by an itchy blister-like rash and preventable with a vaccine. Measles and chickenpox cases are rising due to declining vaccination rates, misinformation about vaccines, increased global travel, and outbreaks in unvaccinated populations, leading to the re-emergence of these preventable diseases. Proquad, a combination vaccine for measles, mumps, rubella, and varicella (chickenpox), helps protect against these diseases by providing immunity through a single dose, reducing the risk of infection, controlling outbreaks, and ensuring comprehensive coverage to prevent complications associated with measles and chickenpox. For instance, in May 2024, according to the World Health Organization, a Switzerland-based non-profit organization, 56,634 measles cases and four deaths were officially reported across 45 out of 53 countries in the WHO European Region during the first three months of 2024. Throughout 2023, 61,070 cases and 13 deaths were reported by 41 countries. Therefore, the rising incidence of measles and chickenpox is driving the growth of the Proquad market.

Get Your Proquad Market Report Here:
https://www.thebusinessresearchcompany.com/report/proquad-global-market-report

What Is the projected market size and growth rate for the proquad market?
The Proquad market size has shown XX (HCAGR) in recent years. It will rise from $XX million in 2024 to $XX million in 2025, at a compound annual growth rate (CAGR) of XX%. The growth is driven by established immunization schedules, the advantages of combination vaccines, government-supported vaccination programs, epidemic outbreaks, strong healthcare infrastructure, and regulatory approvals.

The Proquad market size is expected to grow to $XX million by 2029 at a CAGR of XX%. Growth is driven by population growth, improved access to healthcare, global health initiatives, rising awareness of vaccine-preventable diseases, and government vaccination funding. Trends include global vaccination coverage, advancements in vaccine delivery technologies, integration of vaccines in routine health systems, improved vaccine accessibility, and increased awareness of vaccine safety.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20349&type=smp

What new trends are reshaping the proquad market and its opportunities?
One significant trend in the ProQuad market is the emphasis on broadening the range of vaccine administration methods, most notably the intramuscular (IM) method, to improve consistency and ease in vaccination procedures. Intramuscular (IM) application involves the direct insertion of the medication or vaccine into the muscle tissue, resulting in quicker absorption into the bloodstream. For instance, in March 2023, the U.S.-based pharmaceutical company, Merck & Co. Inc., was granted U.S. Food and Drug Administration (FDA) approval for the incorporation of an intramuscular (IM) route of administration to the U.S. Product Insert (USPI) for its collection of MMRV vaccines, including ProQuad. This approval made the MMRV group comply with other routinely suggested vaccines that can be administered intramuscularly. Healthcare practitioners in the U.S .are now presented with the opportunity to administer all the conventionally recommended pediatric vaccines on the CDC immunization routine through the same intramuscular route. Of all measles, mumps, rubella, and varicella vaccines approved for IM administration in the U.S., only M-M-R II, VARIVAX, and ProQuad are eligible. The MMRV range of vaccines has also been licensed for IM utilization in the European Union.

What major market segments define the scope and growth of the proquad market?
The proquad market covered in this report is segmented -

1) By Indication: Measles; Mumps; Rubella; Varicella
2) By Patient Type: Pediatric Patient; Adult Patient
3) By End User: Healthcare Providers; Pharmacies; Public Health Organization

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20349

Which region dominates the proquad market?
North America was the largest region in the proquad market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which key market leaders are driving the proquad industry growth?
Major companies operating in the proquad market are Merck and Co. Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20349&type=smp

What Is Covered In The Proquad Global Market Report?

•Market Size Forecast: Examine the proquad market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the proquad market for a structured understanding.
•Key Players Overview: Analyze major players in the proquad market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the proquad market.
•Segment Contributions: Evaluate how different segments drive overall growth in the proquad market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the proquad market.
•Industry Challenges: Identify potential risks and obstacles affecting the proquad market.
•Competitive Landscape: Review strategic developments in the proquad market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.